Guanethidine blocks the 2-deoxy-D-glucose-induced hypothalamic noradrenergic drive to hyperglycemia.
To determine whether 2-deoxy-D-glucose (2-DG)-induced hyperglycemia is neurally mediated we administered guanethidine, an adrenergic neuron blocker, to 2-DG-treated rats. While 2-DG increased both medial basal hypothalamic noradrenergic neuronal activity (MBH NNA) and serum glucose, the rise in serum glucose was blocked by guanethidine while MBH NNA was even further increased. We conclude that 2-DG-induced hypothalamic noradrenergic drive to hyperglycemia is mediated by direct sympathetic nervous system activation of liver glucose output.
D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D003837:Deoxy Sugars / Q000037:antagonists & inhibitors*; D003847:Deoxyglucose / Q000037:antagonists & inhibitors*; D005947:Glucose / Q000378:metabolism; D006145:Guanethidine / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000032:analysis; D009638:Norepinephrine / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D013564:Sympathetic Nervous System / Q000187:drug effects*; D014697:Ventromedial Hypothalamic Nucleus / Q000032:analysis / Q000187:drug effects*
D001786:Blood Glucose; D003837:Deoxy Sugars; D008734:Methoxyhydroxyphenylglycol; D003847:Deoxyglucose; D005947:Glucose; C010117:3,4-dihydroxyphenylglycol; D009638:Norepinephrine; D006145:Guanethidine